Novo Nordisk A/S ADR Stock
€119.00
Your prediction
Novo Nordisk A/S ADR Stock
Pros and Cons of Novo Nordisk A/S ADR in the next few years
Pros
Cons
Performance of Novo Nordisk A/S ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR | 0.850% | 3.030% | -0.418% | -20.667% | 26.866% | 93.811% | 171.689% |
| Bayer AG ADR | -3.790% | 0.794% | 0.000% | -57.095% | -26.163% | -53.309% | -59.032% |
| Roche Holding AG ADR | 0.440% | -0.961% | -2.188% | -19.389% | -12.600% | -18.186% | - |
| GSK plc ADR | 0.000% | 3.243% | -4.020% | 17.178% | 13.690% | -2.675% | -15.766% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Upon first glance, the financials of Novo Nordisk, a leading pharmaceutical company with the US symbol NVO, appear to be robust and promising. With a solid financial foundation, significant growth in total assets, revenues, and consistent profitability, the company seems to be on a trajectory for success. However, a deep dive into the financial statements reveals various aspects in which investor opinions may diverge.
Revenue Growth: In the past two years, Novo Nordisk has seen an increase in total revenues. Comparing the numbers from 2020 to 2022, total revenue increased from DKK 126.95 billion to DKK 176.95 billion. This shows that the business is growing and gaining significant market share within the pharmaceutical industry.
Steady Profitability: Net income has also seen a positive trend over the past three years. From 2020, net income increased from DKK 42.14 billion to DKK 55.53 billion in 2022. This consistent profitability is a good indicator of the company's financial health and potential for continued growth.
Comments
